BeyPro1: A phase II single-arm study for the treatment after recurrence of advanced melanoma patients harboring the V600BRAF mutation and pretreated with vemurafenib, with the association of vemurafenib plus fotemustine.
Paola Queirolo
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Francesco Spagnolo
Honoraria - Bristol-Myers Squibb; Roche/Genentech
Virginia Picasso
No relevant relationships to disclose
Elena Tornari
No relevant relationships to disclose
Vincenzo Ottaviano
No relevant relationships to disclose
Laura Giorello
No relevant relationships to disclose
Ester Simeone
No relevant relationships to disclose
Antonio Maria Grimaldi
No relevant relationships to disclose
Marcello Curvietto
No relevant relationships to disclose
Domenico Franco Merlo
No relevant relationships to disclose
Paolo Antonio Ascierto
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche/Genentech; Ventana
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Roche/Genentech
Research Funding - Bristol-Myers Squibb; Roche/Genentech; Ventana
Paolo Bruzzi
No relevant relationships to disclose